Forcyte awarded Phase 2 SBIR by NIH / NCATS to develop pseudo-3D contractile “tissuoid” assay enabling study of coordinated cell contractions and tachyphylaxis

Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force plays a big role. These tools will enable researchers to get to functional endpoints faster, using human cells, but without using humans. 384-wellplate products will enable up to 100x improvements in throughput over standard organ tissue bath contraction assays.